Bavarian Nordic A/S has announced the initiation of a Phase 3 clinical study for its chikungunya vaccine, CHIKV VLP, targeting children aged 2 to 11 years. The study, which is the first of its kind for this age group, aims to expand the approved use of the vaccine, currently available for individuals 12 years and older in the US, EU, and United Kingdom under the name VIMKUNYA®. This global, randomized, double-blind, placebo-controlled trial will assess the safety and immunogenicity of the vaccine in 720 children over a period of two years. Results from the study are expected in the first half of 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bavarian Nordic A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001102203-en) on June 12, 2025, and is solely responsible for the information contained therein.